Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Low-dose 10-day decitabine plus venetoclax induced rapid MRD negativity and durable remission in de novo AML and high-risk MDS

Junqing Wu, Xueping Luo, Xiaoyu Liu et al. Nov 03, 2025 pp. 3449-3449 10.1182/blood-2025-3449

Abstract Background The combination of hypomethylating agents (HMAs) and venetoclax (VEN) have emerged as a new standard of care in older or...

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner et al. Nov 03, 2025 pp. 3653-3653 10.1182/blood-2025-3653

Abstract Background: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T lymphocytes with high rates of rela...

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Marwan Kwok, Connor Johnson, Eugen Tausch et al. Nov 03, 2025 pp. 245-245 10.1182/blood-2025-245

Abstract Patients with chronic lymphocytic leukemia (CLL) experience variable clinical course and duration of therapeutic response. While pr...

A quality improvement project to improve the recognition and management of iron delivery in the postpartum patient

Ishan Tatake, Ilona Grigoryan, Ming Lim et al. Nov 03, 2025 pp. 2607-2607 10.1182/blood-2025-2607

Abstract Background: Iron deficiency (ID) is highly prevalent during pregnancy and may affect up to half of pregnancies with more severe ID...

Final results from a prospective, multicenter, non-interventional study (BESREMi-PASS) on the safety of ropeginterferon alfa-2b in 229 patients with polycythemia vera

Veronika Buxhofer-Ausch, Andreas Reiter, Ciprian Tomuleasa et al. Nov 03, 2025 pp. 2032-2032 10.1182/blood-2025-2032

Abstract Introduction Ropeginterferon alfa-2b (ropeg), a next-generation mono-pegylated interferon (IFN) demonstrated a favorable safety and...

Evaluation for non-accidental trauma (NAT) and bleeding disorders in infants referred to pediatric hematology

Abbey Elsbernd, Shannon Carpenter, Lyndsey Hultman et al. Nov 03, 2025 pp. 2677-2677 10.1182/blood-2025-2677

Abstract Introduction: The most common presentation for both pediatric non-accidental trauma (NAT) and bleeding disorders is bruising. In no...

Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study

Rosalyn Marar, Claire Yee, Anna Bodily et al. Nov 03, 2025 pp. 715-715 10.1182/blood-2025-715

Abstract Introduction: Multiple myeloma (MM) predominantly affects older adults who vary widely in physiological status and treatment outcom...

What is the optimal threshold for aberrant lymphoblasts at diagnosis to predict lymphoid transformation in chronic myeloid leukemia?

Zhenzhen Jiang, Xiaoshuai Zhang, Mei Bao et al. Nov 03, 2025 pp. 2001-2001 10.1182/blood-2025-2001

Abstract Abstract Aim: To explore the prognostic proportion of bone marrow aberrant lymphoblasts (ALB) detected by flow cytometry (FCM) for...

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei et al. Nov 03, 2025 pp. 816-816 10.1182/blood-2025-816

Abstract Introduction: CAR-T cell therapy has transformed lymphoid malignancy treatment but remains challenging in AML due to lack of safe t...

Unsupervised clustering of DDX41 mutants informs on the somatic landscape of single germline hits

Arda Durmaz, Carlos Bravo-Perez, Olivia Hunyadi et al. Nov 03, 2025 pp. 1443-1443 10.1182/blood-2025-1443

Abstract Germline DDX41 mutations can occur in monoallelic form or in the context of somatic hits, predominantly R525H. While germline DDX41...

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Georgios Pongas, Matthew Mei, Lu Chen et al. Nov 03, 2025 pp. 2134-2134 10.1182/blood-2025-2134

Abstract Background: Frontline therapy of chronic lymphocytic leukemia (CLL) typically consists of a Bruton tyrosine kinase inhibitor (BTKi)...

Basal and stimulated intra-RBC and exported ATP and RBC adhesivity ex vivo in children with sickle cell disease

Apoorva Jagadish, Youwei Chen, Marilyn Telen et al. Nov 03, 2025 pp. 6488-6488 10.1182/blood-2025-6488

Abstract INTRODUCTION Sickle cell disease (SCD) represents a significant global health burden, and is characterized by hemolytic anemia, vaso...

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Eric Winer, Megan Othus, Ehab Atallah et al. Nov 03, 2025 pp. 5279-5279 10.1182/blood-2025-5279

Abstract Background: MyeloMATCH is an NCI-sponsored initiative for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) employing...

Orelabrutinib for elderly patients with stage IV marginal zone lymphoma involving the central nervous system: A case report and clinical implications

Fang Wei, Shaowei Chen, Yuanjun Zheng et al. Nov 03, 2025 pp. 7110-7110 10.1182/blood-2025-7110

Abstract Background: Marginal zone lymphoma (MZL) is a heterogeneous disease accounting for 7% of non-Hodgkin lymphomas. The lack of a stand...

Babesiosis masquerading as ITP in a patient with CLL

Fawad Talat, Obuli Srinivasan Gurunathan, Rehan Ishaque et al. Nov 03, 2025 pp. 6601-6601 10.1182/blood-2025-6601

Abstract Introduction: We report a case of severe thrombocytopenia, which was initially thought to be a consequence of I...

Pre-transplant physical function and sarcopenia assessment in allogeneic stem cell transplant recipients: A cross-sectional analysis from a multidisciplinary program

Luis Tamargo, David Pozo Crespo, Blanca Mur Molina et al. Nov 03, 2025 pp. 7792-7792 10.1182/blood-2025-7792

Abstract Introduction Advances in allogeneic stem cell transplantation (alloSCT) have improved survival, yet long-term c...

Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)

Maher Abdul-Hay, Colin Vale, Onyee Chan et al. Nov 03, 2025 pp. 768-768 10.1182/blood-2025-768

Abstract Background Common targets for T-cell–redirecting immunotherapies in AML and MDS have previously presented challenges. CLN-049 is a...

Use of simulation-based education to mitigate race- and disease-based discrimination in sickle cell disease care

Zaphrirah Chin, Nicole Bohnker, Collins Odhiambo et al. Nov 03, 2025 pp. 830-830 10.1182/blood-2025-830

Abstract Introduction Patients living with sickle cell disease (SCD) have a life-threatening disease causing a decreased...

BCMA+ extracellular vesicles predict response and toxicity in patients with multiple myeloma treated with anti-BCMA bispecific antibodies

Carmine Liberatore, Francesca D'Ascanio, Pasquale Simeone et al. Nov 03, 2025 pp. 2235-2235 10.1182/blood-2025-2235

Abstract Anti-BCMA bispecific antibodies (BiAbs) improved outcomes of patients (pts) with relapsed/refractory multiple myeloma (RRMM). In th...

Evaluation of PET/CT during upfront therapy as a prognosticator in follicular lymphoma patients at the University of Debrecen

Ádám Jóna, Evelin Kiss, Zsófia Simon et al. Nov 03, 2025 pp. 5348-5348 10.1182/blood-2025-5348

Abstract Introduction: Traditional prognostic indices, while widely used, exhibit limitations in comprehensively delineating the clinical he...

Integrated modeling analyses for belantamab mafodotin in combination with standard of care in patients with Relapsed/Refractory multiple myeloma (RRMM) from dreamm-6, dreamm-7, and dreamm-8

Theodoros Papathanasiou, Fernando Carreño, Patrick Hanafin et al. Nov 03, 2025 pp. 4043-4043 10.1182/blood-2025-4043

Abstract Introduction: Belantamab mafodotin was investigated for RRMM in combination with lenalidomide + dexamethasone in Arm A of the phase...

MDS without clonal marker: When depth outperforms breadth

Sandra Huber, Wencke Walter, Marietta Truger et al. Nov 03, 2025 pp. 2071-2071 10.1182/blood-2025-2071

Abstract Background: Myelodysplastic neoplasms (MDS) are a heterogeneous group of clonal myeloid neoplasms. The interpla...

Mortality trends of chronic lymphocytic leukemia and pneumonia in the United States (1999–2023): A CDC-wonder analysis

Sibgha Fawad Memon, Zauha Fawad Memon, Abdul basit Khan et al. Nov 03, 2025 pp. 6269-6269 10.1182/blood-2025-6269

Abstract INTRODUCTION: Chronic lymphocytic leukemia (CLL) is the most prevalent white blood cell malignancy in the United States and account...

Prevalence, incidence, and outcomes of multiple myeloma patients using electronic health records and natural language processing

María-Victoria Mateos, Roberto Trelles, Fernando Escalante Barrigón et al. Nov 03, 2025 pp. 4566-4566 10.1182/blood-2025-4566

Abstract Background: A comprehensive understanding of multiple myeloma (MM) in real-world settings is essential to improve patient care and...

Discovery of first-in-class calr-targeted precision ADCs delivering a CDK9degrader payload for the treatment of calr-mutated MPNs

Norman Fultang, Ashley Schwab, Sharayu Chandratre et al. Nov 03, 2025 pp. 72-72 10.1182/blood-2025-72

Abstract Myeloproliferative neoplasms (MPNs) are driven by clonal hematopoietic stem cells (HSCs), yet current therapies primarily address s...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page